Volume 78, Pages S10-S21 (August 2010)

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Kamyar Kalantar-Zadeh  Kidney International 
Volume 79, Pages S3-S8 (April 2011)
Vitamin D levels and patient outcome in chronic kidney disease
Pleiotropic effects of the non-calcium phosphate binder sevelamer
A.M. Thompson, T.G. Pickering  Kidney International 
LDL cholesterol in CKD—to treat or not to treat?
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Volume 67, Pages S1-S7 (June 2005)
Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
FGF23 or PTH: which comes first in CKD ?
Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
C-reactive protein and dialysis access
Association of Relatively Low Serum Parathyroid Hormone With Malnutrition- Inflammation Complex and Survival in Maintenance Hemodialysis Patients  Ramanath.
Reassessment of the care of the patient with chronic kidney disease
Volume 79, Pages S24-S27 (April 2011)
C-reactive protein and dialysis access
Volume 79, Pages S3-S8 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Chapter 3: Management of progression and complications of CKD
Volume 88, Issue 2, Pages (August 2015)
Kamyar Kalantar-Zadeh  Kidney International 
Volume 76, Pages S50-S99 (August 2009)
Let Them Eat During Dialysis: An Overlooked Opportunity to Improve Outcomes in Maintenance Hemodialysis Patients  Kamyar Kalantar-Zadeh, MD, MPH, PhD,
Volume 84, Issue 4, Pages (October 2013)
Comorbidity and confounding in end-stage renal disease
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
Pleiotropic effects of the non-calcium phosphate binder sevelamer
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 74, Issue 3, Pages (August 2008)
The new role of calcimimetics as vasculotropic agents
Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps  Vincent M. Brandenburg, Markus.
Volume 79, Pages S20-S23 (April 2011)
Veerle P. Persy, Marc D. McKee  Kidney International 
Volume 80, Issue 2, Pages (July 2011)
Use of vitamin D in chronic kidney disease patients
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
LDL cholesterol in CKD—to treat or not to treat?
The calcium–phosphorus in guidelines for CKD-MBD
Blood pressure targets in hemodialysis patients
Volume 68, Pages S24-S28 (July 2005)
Volume 73, Issue 12, Pages (June 2008)
Volume 74, Pages S88-S93 (December 2008)
Role of vitamin D receptor activators on cardiovascular risk
Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.
Vitamin D levels and patient outcome in chronic kidney disease
Volume 87, Issue 3, Pages (March 2015)
Calcium sensing in podocytes
Volume 68, Issue 3, Pages (September 2005)
Volume 71, Issue 6, Pages (March 2007)
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival.
Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease  C.P. Kovesdy, S. Ahmadzadeh,
Fibroblast growth factor 23: the making of a hormone
Volume 56, Issue 3, Pages (September 1999)
Volume 63, Issue 2, Pages (February 2003)
Volume 72, Issue 2, Pages (July 2007)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Volume 80, Issue 10, Pages (November 2011)
Charles A. Herzog  Kidney International 
Recent developments in the management of secondary hyperparathyroidism
Volume 74, Issue 10, Pages (November 2008)
Volume 83, Issue 1, Pages (January 2013)
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Volume 82, Issue 1, Pages (July 2012)
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Volume 78, Pages S10-S21 (August 2010) Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals  Kamyar Kalantar-Zadeh, Anuja Shah, Uyen Duong, Rulin C. Hechter, Ramanath Dukkipati, Csaba P. Kovesdy  Kidney International  Volume 78, Pages S10-S21 (August 2010) DOI: 10.1038/ki.2010.189 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Parathyroid hormone (PTH) distribution in 130,525 prevalent Japanese hemodialysis patients in 2007.55 Median dialysis vintage is 4 years. Data are abstracted from the ‘Japanese Society for Dialysis Therapy’ registry of dialysis patients (http://www.jsdt.or.jp), which recommends a PTH target range of 80–120pg/ml.54 KDOQI, Kidney Disease Outcome Quality Initiative. Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 2 The U-shaped association between serum intact parathyroid hormone (PTH) and survival in 58,058 maintenance hemodialysis patients over 2 years. KDOQI, Kidney Disease Outcome Quality Initiative; MICS, malnutrition–inflammation complex; VDRA, vitamin D receptor activator. (adapted from Kalantar-Zadeh et al.15) Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 3 Schematic representation of the links between components of kidney bone disease and vascular calcification. Note potential contributors of low parathyroid hormone (PTH) level and its confounded association with poor outcomes. MICS, malnutrition–inflammation complex; VDRA, vitamin D receptor activator. Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 4 A comparison between survival predictability of serum parathyroid hormone (PTH) (as shown inFigure 2) and serum alkaline phosphatase in dialysis patients. Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 5 Mean serum alkaline phosphatase according to the tertiles of T score 154 maintenance hemodialysis patients. (adapted from Park et al.80) Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 6 Comparing conventional (fixed covariate) survival models vs time-dependent (repeated measure) models in examining the association between serum calcium and survival in chronic kidney disease patients. Kidney International 2010 78, S10-S21DOI: (10.1038/ki.2010.189) Copyright © 2010 International Society of Nephrology Terms and Conditions